Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 635

Similar articles for PubMed (Select 16504922)

2.
3.

Use of intravenous immunoglobulin therapy in autoimmune blistering diseases.

Ahmed AR.

Int Immunopharmacol. 2006 Apr;6(4):557-78. Epub 2005 Dec 13. Review.

PMID:
16504919
4.

Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy.

Ahmed AR.

Expert Opin Investig Drugs. 2004 Aug;13(8):1019-32. Review.

PMID:
15268639
6.

Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.

Sami N, Bhol KC, Razzaque Ahmed A.

Clin Immunol. 2002 Jan;102(1):59-67.

PMID:
11781068
7.

High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.

Segura S, Iranzo P, Martínez-de Pablo I, Mascaró JM Jr, Alsina M, Herrero J, Herrero C.

J Am Acad Dermatol. 2007 Jun;56(6):960-7. Epub 2007 Mar 21.

PMID:
17368865
10.

The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid.

Miserocchi E, Baltatzis S, Roque MR, Ahmed AR, Foster CS.

Ophthalmology. 2002 Jan;109(1):111-8.

PMID:
11772589
11.

Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.

Keskin DB, Stern JN, Fridkis-Hareli M, Razzaque Ahmed A.

Cytokine. 2008 Mar;41(3):315-21. doi: 10.1016/j.cyto.2007.12.007. Erratum in: Cytokine. 2008 Aug;43(2):229.

PMID:
18289869
12.

Dermatological uses of high-dose intravenous immunoglobulin.

Jolles S, Hughes J, Whittaker S.

Arch Dermatol. 1998 Jan;134(1):80-6. Review.

PMID:
9449914
13.

Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.

Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR.

Ophthalmology. 2004 Jul;111(7):1380-2.

PMID:
15234140
14.

Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid.

Mazzi G, Raineri A, Zanolli FA, Da Ponte C, De Roia D, Santarossa L, Guerra R, Orazi BM.

Transfus Apher Sci. 2003 Feb;28(1):13-8.

PMID:
12620264
15.
16.

Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.

Thorne JE, Woreta FA, Jabs DA, Anhalt GJ.

Ophthalmology. 2008 Dec;115(12):2146-2152.e1. doi: 10.1016/j.ophtha.2008.08.002. Epub 2008 Oct 18.

PMID:
18930554
17.
18.

Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.

Mignogna MD, Fortuna G, Leuci S, Ruoppo E, Adamo D, Fedele S.

Clin Exp Dermatol. 2009 Mar;34(2):145-50. doi: 10.1111/j.1365-2230.2008.02809.x.

PMID:
19187294
19.

Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.

Sami N, Qureshi A, Ruocco E, Ahmed AR.

Arch Dermatol. 2002 Sep;138(9):1158-62.

PMID:
12224976
20.

Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches.

Sacher C, Hunzelmann N.

Am J Clin Dermatol. 2005;6(2):93-103. Review.

PMID:
15799681
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk